Eisai R&d Management Co., Ltd.

Merck Sharp + Dohme Corp.

Sony Corporation

Yu Kato

Ken Ito

Yoshimasa Sakamoto

Junji Matsui

Yoichi Ozawa

Andrew Evan Denker

Kimiyo Tabata

Kishan Agarwala

Yusaku Hori

Masahiko Katayama

Yusuke Adachi

Takanori Abe

Yuya Nakazawa

Sho Tachino

Katsuhisa Suzuki

Kana Hoshino

Katsuya Kita

Mutsuhiro Oomori

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein Ris Calkyl or Ccycloalkyl, Ris a hydrogen atom or Calkoxy, and Ris a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.

Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): 

Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer

The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.

Anti human Notch4 antibody

Growing community of inventors

Tokyo, Japan

Yu Kato